ORIGINAL RESEARCH ARTICLE

Divergent Neuroimmune Signatures in the Cerebrospinal Fluid Predict Differential Gender-Specific Survival Among Patients With HIV-Associated Cryptococcal Meningitis

- 1 Samuel Okurut^{1,2*}, David R Boulware³, Elizabeth Okafor³, Joshua Rhein³, Henry Kajumbula²,
- 2 Bernard Bagaya ⁵, Freddie Bwanga ², Joseph O Olobo⁵, Yukari C Manabe^{1,4}, David B Meya^{1,3,6},
- 3 and Edward N Janoff^{7,8} for ASTRO trial team.
- 4 ¹Translation Sciences Laboratory, Research Department, Infectious Diseases Institute, Makerere
- 5 University, Box 22418, Kampala, Uganda
- 6 ²Department of Medical Microbiology, School of Biomedical Sciences, College of Health Sciences,
- 7 Makerere University, 7072, Kampala, Uganda
- 8 ³Division of Infectious Diseases and International Medicine, Department of Medicine, University of
- 9 Minnesota, Minneapolis, MN, 55455, USA
- ⁴Division of Infectious Diseases, Department of Medicine, John Hopkins University School of
- 11 Medicine, Baltimore, Maryland, MD, 21205, USA
- 12 ⁵Department of Immunology and Molecular Biology, School of Biomedical Sciences, College of
- 13 Health Sciences, Makerere University, Box 7072, Kampala, Uganda
- ⁶Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, 7072,
 Kampala, Uganda
- ⁷Mucosal and Vaccine Research Program Colorado, Department of Medicine, Division of Infectious
- 17 Diseases, University of Colorado Denver, Aurora, Colorado, 80045, USA
- 18 ⁸Denver Veterans Affairs Medical Center, Denver CO, 80045, USA
- *Correspondence to: Samuel Okurut, Infectious Diseases Institute, Makerere University, Box 22418,
 Kampala, Uganda. Email: <u>okuruts@gmail.com</u>, Mobile: +256-782-003931.
- Key words (maximum 8): cryptococcal meningitis 1, gender survival 2, Cerebrospinal fluid 3,
 neuroimmune signatures 4, Principal Component Analysis 5, IL-5 6, CXCL10/IP-10 7, CCL11/Eotaxin
 8
- 26

28

19

- 27 Number of words: (4864 words, maximum 12,000 words)
- 29 Number of Figures and Tables: (9 Figures and or Tables, maximum 15 figures or tables)
- 30
- 31

32 ABSTRACT (310 of 350 words)

33 Survival among people with HIV-associated cryptococcal meningitis (CM) remains low, 34 exceptionally among women with the increased threat of death on current optimal use of antifungal 35 drugs. Cryptococcus dissemination into the central nervous system (CNS) prompts a neuroimmune 36 reaction to activate pathogen concomitant factors. However, no consistent diagnostic or prognostic 37 immune-mediated signature is reported to underpin the risk of death or mechanism to improve 38 treatment or survival. We theorized that the distinct neuroimmune cytokine or chemokine signatures 39 in the cerebrospinal fluid (CSF), distinguish survivors from people who died on antifungal treatment, 40 who may benefit from tailored therapy. We considered the baseline clinical disease features, 41 cryptococcal microbiologic factors, and CSF neuroimmune modulated signatures among 419 42 consenting adults by gender (biological sex assigned at birth) (168 females and 251 males) by 18 weeks 43 of survival on antifungal management. Survival at 18 weeks was inferior among females than males 44 (47% vs. 59%; hazard ratio HR=1.4, 95% CI: 1.0 to 1.9, and p=0.023). Unsupervised principal 45 component analysis (PCA) demonstrated the divergent neuroimmune signatures by gender, survival, 46 and intragender-specific survival. Overall, females displayed lower levels of PD-L1, IL-1RA, and IL-47 15 than males (all $p \le 0.028$). Female survivors compared with those who died, expressed significant 48 fold elevations in levels of CSF (CCL11 - myeloid and CXCL10 - lymphoid chemokine (in both 49 p=0.001), and CSF Th1, Th2, and Th17 cytokines. In contrast, male survivors expressed distinctly 50 lower levels of CSF IL-15 and IL-8 compared with those who died. Survivors of either gender 51 demonstrated a significant increase in the levels of immune regulatory element, IL-10. In the finale, 52 we classified divergent neuroimmune key signatures in CSF by gender, survival, and intragender-53 specific survival among people with HIV-associated cryptococcal meningitis. These intragender-54 specific survival associated-neuroimmune signatures, suggests the discrete role of gender immune 55 regulating mechanisms as the possible targets for interventions to advance therapy to improve survival 56 among people with HIV-associated cryptococcal meningitis.

58 1 INTRODUCTION

59 Co-infection with the fungus Cryptococcus neoformans remains an important contributor to 60 death among people with advanced HIV/AIDS worldwide, reported with the existing ideal use of antifungal medications ^{1,2}. The reported global HIV-associated cryptococcal meningitis (CM) survival 61 62 rates vary by location based on existing HIV prevalence rates. In Europe and North America, with the low prevalence of people with HIV, both the incidence and mortality rates of CM are lowest³, in 63 64 contrast, to low and middle-income countries, especially in Africa with the highest prevalence of 65 people with HIV ³⁻⁵. In countries with high frequency of people with HIV in Africa, like Uganda, 66 Botswana, and South Africa, the 10-week survival rates can fall below 50% ^{3,5–8} reported among closely monitored research settings, with deaths occurring within days to weeks, and sometimes, up to 67 68 months after diagnosis ^{2,9,10}. The high mortality among closely monitored patients with CM may be worrisome, for patients undertaking treatment in public health settings where specialized diagnosis and 69 70 close treatment monitoring may be a challenge. These observations rank highly the importance of early 71 immune response as possible intervention to control fungal infection in supporting better survival ¹⁰.

The Casadevall and Pirofski damage response framework paradigm points to the role of the 72 73 pathological processes in influencing host response mechanisms to shape the infection and disease 74 outcome in sequelae ^{11,12}. That the replicating pathogen eliciting unregulated immune activated mechanism (role of immune regulation), mediate pathways that lead to host self-directed damage 75 76 responses that lead to poor outcome. And that replicating pathogen in a state with immune inhibition 77 or in the absence of the pathogen-specific induced response (case of severe immune suppression), that 78 pathogen-associated virulence factors lead to host damage responses that lead to poor outcomes. 79 Suggesting that improved outcome is achievable in a combined therapy involving an effective 80 pathogen-specific target therapy (e.g., antifungals) combined with immune-based treatment to 81 modulate immune homeostasis.

82 In the immunopathogenesis observations, cryptococcal dissemination into the central nervous system (CNS) tissues and CSF across the blood-brain barrier ^{13–15} leads to activation of CNS resident 83 neuroimmune cells (astrocytes, microglial cells, local macrophages, dendritic cells, and lymphocytes). 84 85 In the process, locally activated immune cells produce activating chemoattractant proteins (e.g., CCL11/Eotaxin, CXCL10/Interferon inducible protein 10 (IP-10) ^{16,17} and other inflammatory 86 87 mediators (e.g., IL-15, IL-8/CXCL8)¹⁸. During cryptococcal infection, CNS infiltrating immunocytes, especially T and B cells ^{19,20}, may extravasate blood vessels and lymphatic channels to induce 88 89 neuroimmune activation, inflammation, and meningoencephalitis. Intracerebral and intrathecal 90 activated cytokine and chemokine production influence neuroimmune milieu-mediated responses, that 91 shape fungal clearance, ensuing immunopathological processes, clinical phenotype, and death outcome 21-25 92

93 Among studies reporting cases by gender, the majority of cryptococcal meningitis is diagnosed among males ^{2,7,9,19,26–44}. Of note, few studies to date since widespread ART rollout specifically address 94 95 selective survival by gender (only five including the current study) ⁷. Only recent data, from 2021 96 reveal that the proportion of females who succumb to fungal disease was higher than in males even in the presence of optimized antifungal and antiretroviral therapy ⁹. Since widespread ART rollout, no 97 such differences in gender-specific survival were reported ^{26,44}. To date, no clear immunopathogenic 98 99 mechanisms have been proposed to explain the divergence in survival by gender despite access to 100 current optimal antifungal treatment and ART.

101 In CM, males show increased expression of innate chemokines and cytokines in the CSF 102 associated with increased trafficking of innate lymphoid and myeloid cells compared with females, ⁷. 103 However, these differences were not evaluated in relation to gender-specific survival. Furthermore, the 104 differences in the host responses to the vaccine induced antigens have been reported by gender in both 105 humans and animals ^{45,46}, showing elevation in cytokine production, endocrine, and metabolic

106 parameters in females compared with males. Nevertheless, in cryptococcal meningitis, the 107 cryptococcal fungal burden, white cell counts, and protein in CSF, and the white cells, and CD4⁺ T cell 108 numbers in blood were similar by gender⁷. The cryptococcal host immune evasion mediating factors, 109 e.g., Cryptococcus fungal vomocytosis and the cryptococcal intracellular fungal proliferation in the 110 cryptococcal infected macrophages, were similar by gender ⁴⁷.

111 We evaluated CSF-specific soluble cytokine, chemokine, and immunoregulatory responses to 112 cryptococcal meningitis between females and males overall, and the differences in these neuroimmune 113 responses in relation to survival by gender (Biological sex assigned at birth). We hypothesized that 114 CSF neuroimmune cytokine and chemokine signatures would differ between females and males and 115 across survival. In the CSF at baseline, we characterized representative Th1, Th2, Th17, Tfh cytokine, 116 and innate myeloid-neutrophils activation regulating cytokines, and immune checkpoint markers (PD-117 L1) among people who survived or died during the 18 weeks of follow-up. We identified discrete 118 differences in patterns of neuroimmune mediators by gender and by intragender-specific survival at 119 the site of infection in the CSF.

MATERIALS AND METHODS 120 2

121 2.1 Participants, Sites, and Setting

122 We enrolled 419 participants from a cohort of adults with CM enrolled to receive meningitis 123 treatment in the Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis 124 trial (ClinicalTrials.gov: NCT01802385). The trial was conducted between 2015 - 2017 at the 125 Infectious Diseases Institute (Administrative site) and at Mulago and Kiruddu National Referral Hospitals (patient catchment sites) in Kampala, Uganda^{2,48}. The participants were selected based on 126 gender and available survival-specific data for cross-sectional analyses with reference to 18 weeks of 127 128 survival after cryptococcal meningitis diagnosis. The majority (94%; 168 females and 251 males) had 129 complete demographic, clinical, and CSF datasets. Participants or their surrogates gave informed 130 written and signed consent under protocols approved by the institutional review board of Makerere 131 University and the University of Minnesota Medical School. Enrolled in the study were people ≥ 18 132 years of age, with a confirmed diagnosis of HIV-associated cryptococcal meningitis co-infection as previously described ^{49,50}. Only participants whose survival status was known at censoring or at study 133 134 termination at 18 weeks of follow-up (379 of 419; 90.5%) were included in the survival sensitivity 135 analyses. Of note, parent cohort survival did not differ statistically between either sertraline 136 randomized participants or those on standard therapy alone 2 .

137 2.2 **Specimen Preparation**

CSF was drawn from lumbar punctures at diagnosis of CM prior to antifungal therapy initiation. 138 139 The CSF specimens were spun to pellet out cells. The CSF supernatant was stored in a -80 °C freezer 140 prior to thawing for testing using Luminex. At enrolment, all participants in the current study were 141 antifungal treatment naïve.

142 Luminex Cytokine and Chemokine Immunophenotyping 2.3

A representative sample of cytokines, chemokines, and checkpoint regulators was measured in 143 144 CSF diluted in a 1:2 ratio based on the R&D Human XL Cytokines Discovery Premixed Kit platform as per the manufacturer's recommendations (R&D, Minneapolis, MN). The T helper 1 (Th1) cytokines 145 146 were tumor necrosis factor-alpha (TNF- α), interferon-gamma (IFN- γ), interleukin 2 (IL-2), IL-12p70, 147 with soluble CD40-Ligand/TNFSF5. The Th2 cytokines were IL-4 and IL-13. T follicular helper 148 cytokines were IL-6 and IL-10. The Th17 cytokines included was IL-17A. Cytokines derived from

149 innate lymphoid and myeloid cells were IL-15, IL-8, IL-1 RA/IL-1 F3. The inflammatory mediating chemokines primarily derived from microglial and astrocytes mediating neuroinflammation in 150 cryptococcal meningitis were CXCL10 lymphoid cells mediating chemoattraction ^{51,52} and CCL11 151 mediating myeloid cells (Eosinophils) chemoattraction ^{53,54}. The IL-8 mediating neutrophils activation 152 and chemoattraction ⁵⁵. The immune checkpoint molecules were programmed death ligand 1 (PD-153 L1/B7-H1) ⁵⁶ and immune regulatory cytokine IL-10 ⁵⁷. 154

155 2.4 **Statistical Analysis**

Data were analyzed using GraphPad Prism version 9.3.0, GraphPad Software, LLC for 156 157 Macintosh (San Diego, California, USA). The databases were compiled using Microsoft Excel. The 158 data variability was visualized using unsupervised Principal Component Analysis, (PCA) using Eigenvector covariates projection on biplots as described elsewhere ^{58–61}. Further interrogation of the 159 160 individual or independent principal component clustering and variability, factor differences, and 161 interactions or associations of independent predictor variables by gender and by survival were 162 performed using univariate and multivariate analyses.

Univariate analytic methods comprised pairwise comparisons using Mann-Whitney non-163 164 parametric U test that compared arithmetic medians and unpaired parametric t-test that compared 165 arithmetic means. In this context of non-normally distributed population variables, statistical 166 differences were reported based on the difference in the sample medians with interquartile ranges 167 (IQR). The univariant difference in the survival outcome or survival risk was determined using Kaplan-168 Meier/Log-rank test (Mantel-Cox Chi-Square test) or Mann-Whitney U-test. The difference in binary 169 outcome was determined using Fisher's exact Chi-square test or Mann-Whitney U-test.

170 In multivariate models, data were Log_2 transformed to normalize the variable prior to the 171 statistical interrogation using multivariate factor analysis and or survival-adjusted logistic regression 172 least square models that measure the risk of likelihood (proportional hazard ratios). In all models, 173 missingness was not imputed. In this context, statistical significance in both the univariate and the 174 multivariate models were based on difference among variables in the original available dataset among 175 participants. The statistical level of the significantly different covariates was reported at a p-value < 0.05 176 and at a 95% level of confidence. The rigor of our interrogations included a large sample size (N=419), 177 controlled comparative covariables at nearly a 1:1 ratio, and minimal missingness with approximately 178 94% data completeness in gender analyses and approximately 90% data completeness in the 18 weeks 179 of survival analyses.

180 3 **RESULTS**

181 3.1 **Baseline Demographics**, by Gender

Consistent with published reports (Figure 1), among 419 participants studied with HIV-182 183 associated CM, the majority were males, who were older and heavier than females (Table 1). About 184 half of these participants were on ART for a median of 1.6 months (IOR; 0 -22 months). Neurologic 185 abnormalities predominated among clinical signs and symptoms, with almost all describing headache for one to four weeks, a third reporting changes in mental status, and a half with abnormal Glasgow 186 187 Coma Score (GCS<15), with each variable reported at comparable frequencies in males and females.

188 As anticipated, CD4⁺ T cell numbers in circulation were low, but were marginally higher in 189 females than males, as were platelet counts and hemoglobin levels (Table 1). CSF protein was not 190 consistently elevated, and WBC counts were low, despite a high burden of yeast. Each result was 191 generally comparable by gender, except CSF glucose which tended to be lower among females than 192 males (Table 1).

193 **3.2** The 18 Weeks Survival on Antifungal Treatment

194 In the parent trial for this analysis, males and females from Uganda and South Africa were 195 randomized 1:1 to receive sertraline (an antidepressant with putative antifungal activity) or standard 196 treatment but showed no differences in survival between treatment groups at 18 weeks². An initial 197 analysis by gender of an expanded data set, from which this current report is derived, showed 198 significantly lower survival among 400 females vs. 577 males (at 50% vs. 57% survival, respectively) 199 at 10 weeks, unadjusted (Hazard Ratio (HR) = 1.20; 95% CI, 1.00-1.45; p= 0.050)⁷. These differences 200 were greater vet in this current subset extended to 18 weeks of observation. Survival among females 201 was 47% (71/150 females) vs. 59% among males (136/230 males) (Mantel-Cox proportional hazard 202 ratio (HR)=1.4 (95% confidence interval, CI: 1.0–1.9); p=0.023) (Figure 2). Of note, survival was 203 similar among males and females in two earlier studies reported prior to ART optimization (before 204 2015) but lower among females in two studies reported after ART optimization (after 2015), which 205 include the current report (Figure 1-2). In the current study, survival overall, and by gender did not 206 differ by ART experience (data not shown).

Survival was similar by gender in the first two weeks of antifungal therapy (Figure 2). However, survival diverged thereafter, remaining consistently lower among females throughout the 18 weeks of observation. As noted, baseline demographics, signs and symptoms, blood and CSF analytes, and cryptococcal fungal burden were relatively similar among participants by gender and by survival (Table 1). Thus, we considered whether the concentrations and the composition of neuroimmuneinduced factors at the site of severe cryptococcal disease in the CSF could underlie subsequent differences in survival by gender over time of observation.

3.3 Significant Differences in Neuroimmune Signatures in Cerebrospinal Fluid by Survival, Gender, and Intragender-Specific Survival.

216 At baseline, we performed unsupervised Principal Component Analysis (PCA) as a primary 217 approach to visualize the data variability and to explore potential unbiased differences in data clustering 218 by gender, survival, and gender-specific survival (Figure 3). The PCA identified individual clusters 219 that offered opportunities to structure downstream data analyses of the indicated model outcomes. The 220 members in the cluster aggregated based on common attributes of the datasets showing high variability 221 and distinct distribution of cytokines and chemokines between females and males (Figure 3A), 222 between survivors and participants who died (Figure 3B), and within gender survival, among females 223 (Figure 3C) and among males (Figure 3D). Eigenvector projections on principal components 1 and 2 224 (PC1 and PC2 respectively) indicated a high probability of neuroimmune variables predicting 225 association with gender and survival outcome (Figure 3 A-D). High Eigenvalues >5 indicate the high 226 capability of the selected covariables in predicting model-associated outcomes (Table below Figure 227 3). For each of the comparative groups, almost all showed such high Eigenvalues and, thereby, the 228 separation between determinants in each group. These distinct patterns for PC1 and PC2 were closely 229 correlated among participants by gender, subject by survival, and females by survival but less so for 230 male survival in which 3 clusters were identified (correlation data not shown). Due to the striking data 231 clustering observed in these groups, we next determined the specific neuroimmune factors contributing 232 to the observed patterns using supervised univariate and multivariate data interrogation approaches.

3.4 Innate Neuroinflammatory Cytokines in the Cerebrospinal Fluid Differ by Gender

The CSF of females with CM at baseline had significantly lower levels of selected innate cytokines than that of their male counterparts, particularly IL-1RA and IL-15, TNF- α and immune checkpoint, PD-L1 (all p<0.050) (**Table 2**). The remainder of the cytokines and chemokines interrogated did not differ significantly by gender but tended to be lower still among females than

males (Table 2). We next considered whether such gender-specific differences were associated with
 the differences in survival by gender.

240 **3.5** Divergent Baseline Neuroimmune Cytokine Signature Predict Intragender Survival

241 **3.5.1** (i). Female Gender-Specific Survival Attributes

242 A number of relevant factors differed between females who survived or died during the 18 243 weeks of observation. The circulating CD4⁺ T cell numbers were generally very low, but median CD4⁺ 244 T cells were 31 cells/ μ L vs. 14 cells/ μ L among females who survived vs. those who died (p=0.009) 245 but did not differ by survival in males (data not shown). Using several alternative models, and after 246 adjusting for cytokines (Table 4 model 1), CXCL10 and CCL11 consistently predicted female survival 247 but not in males. These soluble immune factors were consistently higher in magnitude among female 248 survivors compared to those who died (Table 3). The levels of CXCL10 were significantly higher 249 among females who survived than those who died, (p=0.013) (Table 3). By survival, CXCL10 levels 250 in females who survived correlated with the number of CSF white cell counts (r=0.292, 95% CI: 0.067-251 0.488; p=0.010), but not in males (Supplementary Figure 1). The fungal burden (CFUs) did not 252 correlate with CXCL10 levels by either gender or gender-specific survival (data not shown).

253 The level of CCL11 (a chemoattractant produced by activated astrocytes, lymphocytes, and 254 macrophages), was significantly higher in female survivors than in those who died, but not among 255 males (Table 3). After adjusting for other cytokines, higher CCL11 expression still predicted female 256 but not male survival (Table 4, Model 1). T cell-related factors (e.g., IL-12p70, IL-17A, and IFN- γ) in 257 the univariate models were also consistently increased in females who survived compared to those who 258 died, but not in males (Table 3). The levels of other cytokines and the neutrophils chemokine IL-8 259 showed no difference among females by survival (Table 3). Only the IL-10 level was increased in both 260 genders among those who survived in univariable analysis (Table 3). However, after adjusting for 261 other factors, the levels of IL-10 expression were correlated with only female survival, but not with 262 male survival (Table 4, Models 2 and 3), as was IL-2 (Table 4, Model 3).

In summary, although immune parameters were lower among all females vs. males, the females who survived showed consistently elevated levels of both myeloid-derived chemokines (CCL11), lymphoid-derived chemokine (CXCL10), T cell-derived cytokines, and the regulatory molecule PD-L1, the differences that were mostly distinct to survival in females, but not in males (Supplementary Figure 1).

268 **3.5.2** (ii). Male Gender-Specific Survival Attributes

269 Males who survived had significantly higher hemoglobin compared with those who died, even 270 after adjusting for the platelet counts and CD4+ T cell counts (Table 4, Model 3). Males, but not 271 females, who survived had significantly lower IL-15 than those who died (Table 3), even after 272 adjusting for other cytokines (Table 4, all Models). The IL-15 levels were independent of fungal 273 burden (CFUs) and CSF white cell counts (data not shown). After adjusting for other factors, lower 274 levels of the neutrophil chemoattractant IL-8 also consistently predicted male survival but not among 275 females (Table 4, Models 1, 3-4). Unlike in males, neither low levels of IL-15 nor IL-8 were associated 276 with survival in females. As noted above, elevated levels of regulatory IL-10 were associated with 277 survival in both genders but did not correlate with male survival (Supplementary Figure 1).

278 4 DISCUSSION

In a large cohort of adults with CM in Uganda on anti-fungal therapy, survival among females was significantly lower compared with that of their male counterparts. Evaluating gender-specific mortality is uncommon in this context (only 5 including the current 21 studies; Supplemental Table

S1), Unlike two previous studies which showed no difference in mortality by gender reported ^{26,44}, the 282 two studies showing such a differences ^{7,42} were performed in people treated with antifungal therapy, 283 284 which helps control fungal burden. Combining antifungal drugs with immunomodulatory interventions 285 could limit the fungal assault on the CNS, illustrated by brain lesions from magnetic resonance imaging 286 and from autopsy examinations among cases with neurological focal infections ^{62–65}. With appreciable 287 control of fungal burden, immune responses may be the more prominent determinant of clinical 288 outcomes.

289 We have identified distinct immune-biological differences in CSF by gender and gender-290 specific survival. The signatures associated with survival in females are distinctive from those in males. 291 These differences were independent of baseline clinical features and cryptococcal fungal burden 292 (CFUs). Most consistent in both the univariate and in multivariate gender-associated survival 293 predictive models were the lower levels of CSF CXCL10/IP-10 and CCL11/Eotaxin that distinguished 294 females who died from survivors, but not males. In contrast, high levels of IL-15 and IL-8 differentiated 295 males who died matched to those who survived, but not females. Several T cell cytokines (IFN-y, TNF-296 α, IL-13, and IL-17A) similarly exhibited diminished levels of expression in females who died matched 297 survivors, but not in males. Lower levels of immune regulatory IL-10 expression were linked with an 298 increased threat of death in both genders. Thus, the biological significance of gender-specific CSF 299 immune signatures suggested among participants with CM may underlie important immune-based 300 mechanisms indispensable to improving antifungal treatment and survival predominantly in women 301 with demonstrated distinct survival-associated cytokine and chemokine patterns.

302 Consistent with the univariate model observations, improved survival at 2-10 weeks was 303 associated with elevation in the levels of soluble CSF cytokines Th1 IL-2, IFN-γ, TNF-α, Th2 IL-4, and Th17 IL-17A, together with innate IL-6 cytokine ^{66,67}. Soluble T-lymphokines levels in CSF are 304 proposed to derive from CXCL10⁶⁸ and CCL11⁶⁹ mediated stimulation of CNS resident immune cells. 305 Moreover, the use of cryptococcal antigens (such as GXM) to stimulate peripheral immunocytes 306 307 demonstrated, that patients with improved 10 weeks survival had increased expression of these 308 cytokines among polyfunctional differentiated CD4 T cells ⁶⁷. Other chemokines demonstrated to 309 predict improved survival included the elevated levels of monocytes chemotactic protein-1 and 310 macrophages inflammatory protein-1⁶⁶. Despite demonstrated correlates of survival in the peripheral circulation ^{70,71}, the importance of characterizing immune responses in the CNS, at the foci of infection, 311 cannot be underestimated since CNS responses in larger studies do not often correlate with those in the 312 313 peripheral circulation ^{70,71}. The disparity between peripheral and CNS observed responses is a 314 characteristic indicator of local mechanisms that influences responses. Compartment-specific responses have been noted previously ^{19,20} and argue that we should be investigating the response in 315 316 CSF. Thus, the current study is unique in characterizing the distinctive neuroimmune signatures 317 defining survival by gender in CNS, at the foci of disease.

318 In theory, the microbial invasion of the CNS activates resident immune cells to produce 319 neuroimmune cellular activating cytokines, chemoattractant chemokines, and surrounding tissue basal 320 cellular immune mediators (prostaglandins, leukotrienes, et cetera). Diverse effector cells include 321 resident microglial, astrocytes, oligodendrocytes, CNS surveillance phagocytes (monocytes, 322 macrophages, neutrophils), dendritic cells, adaptive T and B cells, innate (natural killer cells), and basal 323 barrier epithelial cells ⁷². Other cells may be drawn by extravasation and diapedesis through the 324 protective vascular barriers to infiltrate the CNS in response to infection and/or to ensuing meningoencephalitis ^{19,20}. The consistent use of antifungal therapy in this study helps to control fungal 325 replication and the burden of fungi ^{2,9,26,73}. With relatively effective antifungal therapy modeling 326 327 immune factors highlights the role of the immune system in determining immune-mediated damage vs. protection in the CSF, and ultimately disease outcome ^{67,74,75}. 328

329 Although cryptococcal fungal burden and other clinical parameters in blood or in CSF did not 330 differ by gender or gender-associated survival, increased production of IL-1RA, IL-15, and PD-L1 in

331 the CSF of males overall may have influenced their poor survival than in their female counterparts. Lower male but not female survival was associated with high levels of myeloid cytokines, including 332 333 the pleiotropic IL-15 and neutrophil-activating factors IL-8, which may influence poor survival in 334 males by the distinctive mechanisms. In literature, IL-8 expression derived from microglia in CNS in response to neuroinflammation ^{76,77}, from monocytes and autocrine IL-8 production by neutrophils 335 enhances immune activation and cellular proliferation ¹⁸. The elevated intrathecal IL-15 and IL-8 in 336 337 the CSF can enhance neutrophils-induced NETosis (Neutrophils traps). The increased neutrophil trap 338 formation may propagate thrombotic vasculitis, cryptococcomas, and fungal occlusions in 339 subarachnoid ventricular and arterial spaces in those with poor survival. Together IL-15 and IL-8 340 elevation can increase local inflammation in the brain, leading to vasculitis in subarachnoid spaces, 341 interfering with blood supply, promoting ischemia, necrosis, and infarction of the brain tissue, and 342 potentially leading to increased risk of death. Thus, the relatively high levels of IL-15 expression 343 among males who died and the inverse relationship of IL-15 levels with those of immune regulatory 344 IL-10 and immune checkpoint PD-L1 among males who died highlights the dynamic functional 345 interrelationship of the potential loss of IL-15 immune regulatory function in influencing the greater 346 risk of death among patients presenting with this neuroimmunological phenotype. Low levels of IL-15 347 may limit the mitotic division of especially fungal-infected macrophages which may attenuate the propagation of endogenous pathogens in quiescent cells ¹⁸. Thus, the observed low levels of IL-15 and 348 349 IL-8 among male survivors may limit intracellular cryptococcal fungal replication potentially leading 350 to low fungal burden and improved survival.

351 Among neutrophils activated factors that shape neuroimmune response and outcome in CNS 352 infection and in sequelae include observations that neutrophil induced responses exacerbate tissue 353 injury through self-directed host and pathogen-mediated mechanisms ^{78,79}. That neutrophil activation 354 is associated with the propagation of tissue necrosis, hypoxia, and nutritional supply impairment 355 especially among people with sepsis and in those with multiple organ failure, that underlie brain injury 356 ^{78,79}. In this context, activation of neutrophil recruiting cytokines and chemokine, at the foci of 357 infection, in the CNS is detrimental to the host ^{76,78}, leading to the release of toxic granules, that are destructive to connective tissues, leading to vasculitis with tissue necrosis, infarction, hypoxia, and 358 359 potentially death. Indeed, in cryptococcal meningitis, neutrophilia in circulation was associated with poor survival outcome ⁸⁰, brain hypoxia ^{15,81,82}, subarachnoid blood vessel occlusion ⁸³, brain tissue 360 necrosis, and cerebellar infarction ⁶⁴. Subsequently, survivors of cryptococcal meningitis suffered long-361 362 term CNS abnormalities associated with impaired faculty observed in sequelae among people without 363 HIV infection ^{62,84}. The persistent CNS abnormalities in sequelae noted in humans with fungal 364 infections were similar to those observed among mouse models of Alzheimer's disease ⁸⁵. In other fatal 365 meningitis focal infections including tuberculosis meningitis and bacterial meningitis, neutrophils account for the majority of cells in the CSF ^{86,87}. However, neither we nor others have characterized in 366 367 detail the neutrophil myeloid lineages and role among CSF white cells in the setting of CM-associated survival. 368

369 Among key differences in female intragender survival with cryptococcal meningitis, survivors 370 tended to shade into CSF relatively high amount of neuroimmune mediating soluble cytokine and 371 chemokine responses across the panel. The higher levels of Th1 IL-2, IFN- γ , TNF- α , IL-12p70, Th17 372 IL-17A, and immune regulatory IL-10 may influence survival in females by distinct CXCL10 and 373 CCL11 chemokine-stimulated mechanisms. In contrast to females who died, females with higher levels 374 of the myeloid chemokine CCL11 and the lymphoid chemoattractant CXCL10 were more likely to 375 survive, but not men. CXCL10 produced by astrocytes and microglia cells or by CNS resident 376 monocytes, macrophages, and dendritic cells stimulates Th1 cytotoxic CD8 T cells, immune 377 modulatory CD4 T cells, regulatory T cells, NK and regulatory B cells, and regulatory T cells via its CXCR3 receptor-mediated stimulation⁸⁸. The cytotoxic response to infected macrophages is 378 379 potentially enhanced in the presence of elevated chemokine in the central nervous, because infected

cells respond to chemoattractant proteins at the site of infection ^{89,90}, whereas immune regulatory cells 380 can modulate inflammation and cellular activation to stimulate tissue recovery ⁹¹. Thus, independent 381 382 of the baseline CSF cryptococcal CFUs and the baseline clinical features, the CCL11 and CXCL10 383 balance is critical in immune regulation of the Th1/Th2/17 balance, modulation of CNS cellular influx 384 that is important in better survival of host with HIV-associated cryptococcal meningitis.

385 Interleukin (IL)-12 is observed as an important factor in the immune control of *Cryptococcus* 386 meningitis as it is observed to influence mechanisms that inhibited cryptococcal fungal replication among Cryptococcus-infected macrophages in vitro ⁹². In mouse models, early preemptive use of IL-387 12 as an adjuvant promoted survival of mice in early use after cryptococcal fungal ⁹². Whereas the late 388 389 treatment of mice with IL-12 after the establishment of cryptococcal infection resulted in more mice 390 dying from fungal infection-attributable deaths ⁹². In the current study, IL-12p70 was elevated among 391 female survivors but not males. In the CNS IL-12 is produced by dendritic cells, and is observed to 392 regulate T cell, and NK cell function, and influence the differentiation of the Th1 cellular phenotype 393 ⁹³. With the prominence of T cells and B cells, in the CSF with cryptococcal meningitis ^{19,20}, increased 394 IL-12p70 shading into the CSF can enhance fungal-specific immunocytes activation to mediate fungal 395 neuroimmune mechanisms for control and for improved host survival.

396 The Th17 cytokine, IL17A, modulated through RORyt regulatory pathway was observed to 397 work in tandem with Th1-modulated cytokines to regulate neuroimmune responses induced to CNS 398 infections ⁹⁴. In particular, IL-17A activates Th17 immunocytes in response to tissue-resident infection. 399 In cryptococcal model infection, IL-17 promoted the development of majority giants cryptococcal cells 400 that have limited ability to cross the blood-brain barrier, leading to localized cryptococcal fungal 401 infection with limited spread to the brain parenchyma where it would cause lethal disease ^{65,95}. Among 402 females, IL-17A was upregulated among those with better survival outcomes. Other Th1 cytokines 403 upregulated among females survivors included IFN- γ , TNF- α and their immune activating factors, 404 CD40 ligand that was demonstrated to facilitate the formation of reactive phagosomes, activation of 405 reactive oxygen and nitrogen species that mediate endogenous killing mechanisms of Cryptococci 406 ingesting macrophages ^{65,95}. Collectively, these immune activating complementary factors, were each increased with increased survival among females. And in the aggregate, these novel findings (reported 407 408 for the very first in the setting of CM gender-specific survival), drive the question as to how these 409 results may be harnessed for targeted gender-specific therapy to optimize survival where fatal 410 outcomes seem to be propagated by immune-mediated mechanisms that appear to operate independent 411 of the fungal burden, clinical presentation, and current antifungal therapy.

412 5 **CONCLUSION**

413 Survival from HIV-associated CM remains significantly lower in females. We found novel 414 distinctive and divergent intragender-associated CSF cytokine signatures at the time of clinical 415 presentation that was independent of the baseline fungal burden and clinical features. Among females, 416 increased concentration of CCL11, CXCL10, and T cell subset associated cytokines mediating the Th1 417 and th17 fungal immunopathogenesis pathways to be divergently augmented with female survival but 418 not in males. However, among males, low levels of the neutrophil-activating chemokines IL-8 and the 419 pleiotropic cytokine, IL-15 potentially fashion antifungal regulation neuroimmune milieu, distinctively 420 expressed with improved male survival but not in females. Increased expression of IL-10 and PD-L1 421 regulatory mechanisms accompany improved survival in both genders identifying common features of 422 a successful CSF profile. The elevated induction of CCL11, CXCL10, IL-17A, and IL-12p70 423 neuroimmune cytokine signature by female intragender-specific survival in the CSF and their strong 424 positive correlation to IL-10 and PD-L1 highlight the interdependence of these responses in shaping 425 immune homeostasis and survival associated-neuroimmune modulating milieu. These key 426 observations reveal promising signals to consider the impact of more robust responses in females,

particularly T cell-dependent (CXCL10, Th1/Th17 cytokines), and lower myeloid responses in males
(e.g., IL-15 and IL-8) and their regulators in controlling outcomes. This data point to the potential
neuroimmune mechanistic targets which could be modified to improve treatment and clinical outcomes
in those with reversible deaths with immune-based combination antifungal therapy.

431 6 LIMITATIONS

One limitation is that the cross-sectional, exploratory study design generated data could not explain marker and clinical variations after the baseline and prior to death outcome or censor, which might be key to explaining the factors that underlie the observed gender-survival subjective mechanisms. The differential of myeloid vs. lymphoid white cells in the CSF compartment was largely unavailable. The limitations of our interpretations of the baseline cross-sectional findings could be enhanced with longitudinal data to appropriately capture and model changes in the immune profile from diagnosis to eventual survival or death.

439 7 CONFLICT OF INTEREST

The authors conformed to the International Committee of Medical Journal Editors (ICMJE) article publication criteria. The authors declared no conflict of interest. Study participants or funders had no role in the design, data curation, or intention to publish. Part of this work was presented in an accepted abstract and poster at the Conference on Retroviruses and Opportunistic Infections (CROI) at Seattle Convention Center, Seattle, Washington, 19-22 February 2023 and was published online on CROI website ⁹⁶. SO was a doctoral fellow and the examined thesis abstract was published online by the Makerere University Online Library as a requirement degree award ⁹⁷.

447 8 AUTHOR CONTRIBUTION

448 SO, EO, DBM, ENJ, YCM, DRB, JR, OOJ, HK, BB, and FB, conceptualized the study, framed 449 the hypothesis, and edited the manuscript. SO, YCM, DRB, JR, DBM, and ENJ sourced for funding, 450 designed experiments, guided data analysis, and drafted the manuscript. SO, performed statistical data 451 analysis, compiled the results, put together the first drafted manuscript, and managed the review and 452 publication process. The authors read and approved the final version of the manuscript for online 453 publication.

454 9 FUNDING

455 This work was supported in part by funding from the National Institutes of Health and the 456 National Institute of Allergy and Infectious Diseases R01 AI078934, U01 AI089244, R21 NS065713, 457 R01 AI108479, and T32 AI055433 grants to DBM and DRB; R01 AI108479 grant to JR and R01 458 AI108479 funding to ENJ. National Institute of Neurologic Diseases and Stroke R01 NS086312, R25 459 TW009345, and K24 AI096925 grant to JR. Fogarty International Center D43 TW009771 grant to 460 YCM and R01 NS086312 grant to RJ. GlaxoSmithKline Trust in Science Africa grant COL 100044928 461 grant to SO. DELTAS Africa Initiative DEL-15-011 grant to THRiVE-2, DBM. Wellcome Trust grants 462 107742/Z/15/Z grant to DBM. Veterans Affairs Research Service I01CX001464 grant to ENJ. The 463 Wellcome Trust Training Health Researchers into Vocational Excellence (THRiVE) in East Africa, 464 087540 grant to DBM. United Kingdom Medical Research Council/Wellcome Trust/Department for 465 International Development (MRC MR/M007413/1 grant to JR and the Grand Challenges Canada S4-466 0296-01 grant to JR. Funding agencies had no role in study design, data collection, data analysis plan, 467 preparation of the manuscript, or in the decision to publish.

468 10 ACKNOWLEDGEMENTS

469 We appreciate the study participants for their involvement in the parent study. We thank the 470 ASTRO trial team for the clinical management of patients and for data collection including Abdu Musubire, Lilian Tugume, Jane Francis Ndyetukira, Cynthia Ahimbisibwe, Florence Kugonza, Alisat 471 472 Sadiq, Radha Rajasingham, Catherine Nanteza, Kiiza Tadeo Kandole, and Darlisha Williams, Edward 473 Mpoza, Fiona Cresswell, Andrew Akampurira, Apio Alison, Caleb Skipper, Kenneth Ssebambulidde, 474 and Mahsa Abassi. We thank the institutional contribution from Infectious Diseases Institute from 475 Bosco Kafufu, Andrew Kambugu. We thank the PhD program mentorship support received from; 476 Infectious Diseases Institute Capacity Building Unit especially from Barbara D. Castelnuovo, Aidah 477 Nanvuma, Stephen Okoboi, and the Statistics unit, especially from Agnes Kiragga. John Hopkins 478 University, School of Medicine and Bloomberg School of Public Health, Department of Molecular 479 Microbiology, and Immunology, especially from Robert R. Bollinger and Arturo Casadevall. University of Colorado, Denver, Anschutz Medical Campus Aurora, Division of Infectious Disease, 480 481 Department of Medicine and Veteran Affairs Research Services especially from Brent Palmer, Tina 482 Powell, and Jeremy Rakhola. We thank the statistical data analysis mentorship received from the 483 University of Minnesota, especially from Ananta S. Bangdiwala and Kathy Hullsiek Huppler.

484 11 ETHICAL CONSIDERATIONS

Participants provided prospective informed written and signed consent and storage consent for specimen use in future studies. Makerere University Higher Degrees Research and Ethics Committee of the School of Biomedical Sciences granted a waiver of informed consent and ethical approvals to analyze the data. The protocol was registered and approved by the National Council of Science and Technology. The parent clinical trial was approved by the National Drug Authority and by the Uganda National Council for Science and Technology. The patient's identifiers were alphanumeric coded and could not identify those patients during the data search.

492 **12 CONTRIBUTIONS TO THE FIELD**

493 The study involved a large sample size with equal ratios between comparative variables that 494 give strong confidence to weighted treatment outcome predictors of HIV-associated cryptococcal 495 meningitis. We discovered the critical role of biological gender in the assessment of survival among 496 patients with HIV-associated cryptococcal meningitis with discrepant bias in women's poor survival. 497 And that immune response differs within gender-specific survival. Together we highlighted the 498 potential role of neuroimmune mechanisms in contributing to the differences in biological gender in 499 survival. The observed immune mechanism illustrates the potential ability of the underlying stimulus 500 in advancing immune-based treatment to work in synergy to improve the efficacy of antifungal drugs 501 to improve survival among preventable deaths.

502 Interim, we propose close immune monitoring of CCL11/Eotaxin, CXCL10/IP-10, IL-12p70, 503 and IL-17A as key indicators of the beneficial Th1 neuroinflammatory cytokine milieu among HIV 504 and cryptococcal meningitis diagnosed women. We recommended mechanisms to augment 505 CCL11/Eotaxin, CXCL10/IP-10, IL-12p70, and IL-17A cytokine deficient among women in addition 506 to interventions to holistically refurbish the dysregulated or exhausted immune response among those 507 co-infected in an attempt to significantly improve women's survival outcome. We propose close 508 monitoring of IL-15, IL-8/CXCL8 together with IL-10 and PD-L1/B7-H1 dysregulation as key 509 indicators of men's poor survival leading pathway. We recommend mechanisms to restore IL-15 and 510 IL-8/CXCL8, IL-10, and PD-L1/B7-H1 checkpoint responses to improve men's survival outcomes. It 511 is plausible that switching the CCL11/Eotaxin and CXCL10/IP-10 chemokine balance in later stages

- 512 of disease progression to a potentially myeloid pathway can lead to a significant self-reliant neuro-
- 513 injury inflicting pathway leading to poor survival outcomes.

514 13 REFERENCES

- Wake RM, Govender NP, Omar T, et al. Cryptococcal-related mortality despite fluconazole
 preemptive treatment in a cryptococcal antigen screen-and-treat program. *Clinical Infectious Diseases*. 2020;70(8):1683-1690. doi:10.1093/cid/ciz485
- Rhein J, Huppler Hullsiek K, Tugume L, et al. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. *The Lancet Infectious diseases*. 2019;19(8):843-851. doi:10.1016/S1473-3099(19)30127-6
- Hakyemez IN, Erdem H, Beraud G, et al. Prediction of unfavorable outcomes in cryptococcal meningitis: results of the multicenter Infectious Diseases International Research Initiative (ID-IRI) cryptococcal meningitis study. *European Journal of Clinical Microbiology and Infectious Diseases*. 2018;37(7):1231-1240. doi:10.1007/s10096-017-3142-1
- Tenforde MW, Jarvis JN. HIV-associated cryptococcal meningitis: ongoing challenges and new opportunities. *The Lancet Infectious Diseases*. 2019;19(8):793-794. doi:10.1016/S1473-3099(19)30295-6
- 5. Stott KE, Loyse A, Jarvis JN, et al. Cryptococcal meningoencephalitis: time for action. *The Lancet Infectious Diseases*. 2021;21(9):e259-e271. doi:10.1016/S1473-3099(20)30771-4
- 6. Boulware DR, von Hohenberg M, Rolfes MA, et al. Human immune response varies by the degree
 of relative cryptococcal antigen shedding. *Open Forum Infectious Diseases*. 2016;3(1):1-7.
 doi:10.1093/ofid/ofv194
- 533 7. Stadelman AM, Ssebambulidde K, Tugume L, et al. Impact of biological sex on cryptococcal
 534 meningitis mortality in Uganda and South Africa. *Medical Mycology*. 2021;59(7):712-719.
 535 doi:10.1093/mmy/myaa108
- 8. Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated
 cryptococcal meningitis: an updated analysis. *The Lancet Infectious diseases*. 2017;17(8):873881. doi:10.1016/S1473-3099(17)30243-8
- Boulware DR, Meya DB, Muzoora C, et al. Timing of Antiretroviral Therapy after Diagnosis of
 Cryptococcal Meningitis. *New England Journal of Medicine*. 2014;370(26):2487-2498.
 doi:10.1056/nejmoa1312884
- Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before
 and after the availability of highly active antiretroviral therapy. *Clinical Infectious Diseases*.
 2008;46(11):1694-1701. doi:10.1086/587667
- 545 11. Casadevall A, Pirofski L anne. The damage-response framework of microbial pathogenesis.
 546 Nature reviews Microbiology. 2003;1(1):17-24. doi:10.1038/nrmicro732

- 547 12. Casadevall A, Pirofski LA. Host-pathogen interactions: Basic concepts of microbial
 548 commensalism, colonization, infection, and disease. *Infection and Immunity*. 2000;68(12):6511549 6518. doi:10.1128/IAI.68.12.6511-6518.2000
- Nielsen K, Cox GM, Litvintseva AP, et al. Cryptococcus neoformans α strains preferentially
 disseminate to the central nervous system during coinfection. *Infection and Immunity*.
 2005;73(8):4922-4933. doi:10.1128/IAI.73.8.4922-4933.2005
- Santiago-Tirado FH, Onken MD, Cooper JA, Klein RS, Doering TL. Trojan horse transit
 contributes to blood-brain barrier crossing of a eukaryotic pathogen. *mBio*. 2017;8(1).
 doi:10.1128/mBio.02183-16
- 556 15. Okurut S, Boulware DR, Olobo J, Meya DB. Landmark clinical observations and
 557 immunopathogenesis pathways linked to HIV and Cryptococcus fatal central nervous system co 558 infection. *Mycoses*. 2020;63(8):840-853. doi:10.1111/myc.13122
- 16. Elsegeiny W, Marr KA, Williamson PR. Immunology of Cryptococcal Infections: Developing a
 Rational Approach to Patient Therapy. *Frontiers in immunology*. 2018;9:651.
 doi:10.3389/fimmu.2018.00651
- 562 17. Chang CC, Omarjee S, Lim A, et al. Chemokine levels and chemokine receptor expression in the
 563 blood and the cerebrospinal fluid of HIV-infected patientswith cryptococcal meningitis and
 564 cryptococcosis- Associated immune reconstitution inflammatory syndrome. *Journal of Infectious* 565 *Diseases*. 2013;208(10):1604-1612. doi:10.1093/infdis/jit388
- Perera PY, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in inflammation and
 immune responses to infection: Implications for its therapeutic use. *Microbes and Infection*.
 2012;14(3):247-261. doi:10.1016/j.micinf.2011.10.006
- Meya DB, Okurut S, Zziwa G, et al. Cellular immune activation in cerebrospinal fluid from
 ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome.
 Journal of Infectious Diseases. 2015;211(10):1597-1606. doi:10.1093/infdis/jiu664
- Okurut S, Meya DB, Bwanga F, et al. B cell Compartmentalization in Blood and Cerebrospinal
 Fluid of HIV-Infected Ugandans with Cryptococcal Meningitis. Noverr MC, ed. *Infection and Immunity*. 2020;88(3):1-14. doi:10.1128/IAI.00779-19
- 575 21. Esher SK, Zaragoza O, Alspaugh JA. Cryptococcal pathogenic mechanisms: A dangerous trip
 576 from the environment to the brain. *Memorias do Instituto Oswaldo Cruz*. 2018;113(7):1-15.
 577 doi:10.1590/0074-02760180057
- Mora DJ, Fortunato LR, Andrade-Silva LE, et al. Cytokine profiles at admission can be related
 to outcome in AIDS patients with cryptococcal meningitis. *PLoS ONE*. 2015;10(3):1-17.
 doi:10.1371/journal.pone.0120297
- Xu XG, Pan WH, Bi XL, et al. Comparison of clinical features in patients with persistent and
 nonpersistent cryptococcal meningitis: Twelve years of clinical experience in four centers in
 china. *CNS Neuroscience and Therapeutics*. 2013;19(8):625-631. doi:10.1111/cns.12135

- 584 24. Rhein J, Hullsiek KH, Tugume L, et al. HHS Public Access. 2020;19(8):843-851.
 585 doi:10.1016/S1473-3099(19)30127-6.Adjunctive
- Rolfes MA, Hullsiek KH, Rhein J, et al. The effect of therapeutic lumbar punctures on acute
 mortality from cryptococcal meningitis. *Clinical Infectious Diseases*. 2014;59(11):1607-1614.
 doi:10.1093/cid/ciu596
- Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: Implications for improving outcomes.
 Clinical Infectious Diseases. 2014;58(5):736-745. doi:10.1093/cid/cit794
- 592 27. Lawrence DS, Leeme T, Mosepele M, Harrison TS, Seeley J, Jarvis JN. Equity in clinical trials
 593 for hiv-associated cryptococcal meningitis: A systematic review of global representation and
 594 inclusion of patients and researchers. *PLoS Neglected Tropical Diseases*. 2021;15(5):1-19.
 595 doi:10.1371/journal.pntd.0009376
- Pappas PG, Bustamante B, Ticona E, et al. Recombinant Interferon-γ1b as Adjunctive Therapy
 for AIDS-Related Acute Cryptococcal Meningitis. *The Journal of Infectious Diseases*.
 2004;189(12):2185-2191. doi:10.1086/420829
- Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation
 in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory
 syndrome. *The Journal of infectious diseases*. 2010;202(6):962-970. doi:10.1086/655785
- 802 30. Rajasingham R, Rhein J, Klammer K, et al. Epidemiology of meningitis in an HIV-infected
 803 Ugandan cohort. *American Journal of Tropical Medicine and Hygiene*. 2015;92(2):274-279.
 804 doi:10.4269/ajtmh.14-0452
- George IA, Santos CAQQ, Olsen MA, Powderly WG. Epidemiology of cryptococcosis and
 cryptococcal meningitis in a large retrospective cohort of patients after solid organ
 transplantation. *Open Forum Infectious Diseases*. 2017;4(1):1-7. doi:10.1093/ofid/ofx004
- 808 32. Rhein J, Morawski BM, Hullsiek KH, et al. Associated Cryptococcal Meningitis: an open-label
 809 dose-ranging study. *Lancet Infect Dis.* 2017;16(7):809-818. doi:10.1016/S1473-3099(16)000748.Efficacy
- 611 Kashef Hamadani BH, Franco-Paredes C, McCollister B, Shapiro L, Beckham JD, Henao-33. 612 Martínez AF. Cryptococcosis and cryptococcal meningitis: New predictors and clinical outcomes States academic 613 United medical centre. Mycoses. 2018;61(5):314-320. at а 614 doi:10.1111/myc.12742
- 615 34. Meya DB, Kiragga AN, Nalintya E, ... Reflexive laboratory-based cryptococcal antigen screening
 616 and preemptive fluconazole therapy for cryptococcal antigenemia in HIV-infected individuals
 617 with Journal of acquired 2019;80(2):182-189.
- Bastick KA, Bangdiwala AS, Abassi M, et al. Seizures in Human Immunodeficiency Virus Associated Cryptococcal Meningitis: Predictors and Outcomes. *Open Forum Infectious Diseases*.
 2019;6(11):1-7. doi:10.1093/ofid/ofz478

- 36. Lakoh S, Rickman H, Sesay M, et al. Prevalence and mortality of cryptococcal disease in adults
 with advanced HIV in an urban tertiary hospital in Sierra Leone: A prospective study. *BMC Infectious Diseases*. 2020;20(1):1-7. doi:10.1186/s12879-020-4862-x
- Marr KA, Sun Y, Spec A, et al. A multicenter, longitudinal cohort study of cryptococcosis in
 human immunodeficiency virus-negative people in the United States. *Clinical Infectious Diseases*. 2020;70(2):252-261. doi:10.1093/cid/ciz193
- 38. Lee WJ, Ryu YJ, Moon J, et al. Enlarged periventricular space and periventricular lesion
 extension on baseline brain MRI predicts poor neurological outcomes in cryptococcus
 meningoencephalitis. *Scientific Reports*. 2021;11(1):1-11. doi:10.1038/s41598-021-85998-6
- 630 39. Kalata N, Ellis J, Kanyama C, et al. Short-term Mortality outcomes of HIV-Associated
 631 cryptococcal meningitis in antiretroviral therapy-naïve and -experienced patients in sub-saharan
 632 Africa. Open Forum Infectious Diseases. 2021;8(10):1-5. doi:10.1093/ofid/ofab397
- 40. Mansoor A e.Rehman, Thompson J, Sarwari AR. Delays in lumbar puncture are independently
 associated with mortality in cryptococcal meningitis: a nationwide study. *Infectious Diseases*.
 2021;53(5):361-369. doi:10.1080/23744235.2021.1889656
- 41. Deiss R, Loreti CV, Gutierrez AG, et al. High burden of cryptococcal antigenemia and meningitis
 among patients presenting at an emergency department in Maputo, Mozambique. *PLoS ONE*.
 2021;16(4 April):1-11. doi:10.1371/journal.pone.0250195
- 42. Zhao T, Xu XL, Nie JM, et al. Establishment of a novel scoring model for mortality risk prediction
 in HIV-infected patients with cryptococcal meningitis. *BMC Infectious Diseases*. 2021;21(1):110. doi:10.1186/s12879-021-06417-9
- 43. Jarvis JN, Lawrence DS, Meya DB, et al. Single-Dose Liposomal Amphotericin B Treatment for
 Cryptococcal Meningitis. *New England Journal of Medicine*. 2022;386(12):1109-1120.
 doi:10.1056/nejmoa2111904
- 645 44. Baldassarre R, Mdodo R, Omonge E, et al. Mortality after clinical management of aids-associated
 646 cryptococcal meningitis in Kenya. *East African Medical Journal*. 2014;91(5):145-151.
- Furman D, Hejblum BP, Simon N, et al. Systems analysis of sex differences reveals an
 immunosuppressive role for testosterone in the response to influenza vaccination. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(2):869-874.
 doi:10.1073/pnas.1321060111
- 46. Fink AL, Engle K, Ursin RL, Tang WY, Klein SL. Biological sex affects vaccine efficacy and
 protection against influenza in mice. *Proceedings of the National Academy of Sciences of the*United States of America. 2018;115(49):12477-12482. doi:10.1073/pnas.1805268115
- Garelnabi M, Taylor-Smith LM, Bielska E, Hall RA, Stones D, May RC. Quantifying donor-todonor variation in macrophage responses to the human fungal pathogen Cryptococcus
 neoformans. *PLoS ONE*. 2018;13(3):1-12. doi:10.1371/journal.pone.0194615

- 48. Rhein J, Morawski BM, Hullsiek KH, et al. Efficacy of adjunctive sertraline for the treatment of
 HIV-associated cryptococcal meningitis: an open-label dose-ranging study. *The Lancet Infectious diseases*. 2016;16(7):809-818. doi:10.1016/S1473-3099(16)00074-8
- 49. Vidal JE, Toniolo C, Paulino A, et al. Performance of cryptococcal antigen lateral flow assay in
 serum, cerebrospinal fluid, whole blood, and urine in HIV-infected patients with culture-proven
 cryptococcal meningitis admitted at a Brazilian referral center. *Revista do Instituto de Medicina Tropical de Sao Paulo*. 2018;60:e1-e1. doi:10.1590/s1678-9946201860001
- 664 50. Rajasingham R, Wake RM, Beyene T, Katende A, Letang E, Boulware DR. Cryptococcal
 665 Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. *Journal of* 666 *clinical microbiology*. 2019;57(1):e01238-18. doi:10.1128/JCM.01238-18
- 51. Vazirinejad R, Ahmadi Z, Arababadi MK, Hassanshahi G, Kennedy D. The biological functions,
 structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple
 sclerosis. *NeuroImmunoModulation*. 2014;21(6):322-330. doi:10.1159/000357780
- 52. Michlmayr D, McKimmie CS. Role of CXCL10 in central nervous system inflammation. *International Journal of Interferon, Cytokine and Mediator Research.* 2014;6(1):1-18.
 doi:10.2147/IJICMR.S35953
- 53. Teixeira AL, Gama CS, Rocha NP, Teixeira MM. Revisiting the role of eotaxin-1/CCL11 in
 psychiatric disorders. *Frontiers in Psychiatry*. 2018;9(JUN):1-6. doi:10.3389/fpsyt.2018.00241
- 54. Parajuli B, Horiuchi H, Mizuno T, Takeuchi H, Suzumura A. CCL11 enhances excitotoxic
 neuronal death by producing reactive oxygen species in microglia. *Glia*. 2015;63(12):2274-2284.
 doi:10.1002/glia.22892
- 55. Mamik MK, Ghorpade A. Chemokine CXCL8 promotes HIV-1 replication in human monocytederived macrophages and primary microglia via nuclear factor-κB pathway. *PLoS ONE*.
 2014;9(3):1-13. doi:10.1371/journal.pone.0092145
- 681 56. Chauhan P, Lokensgard JR. Glial cell expression of PD-L1. *International Journal of Molecular* 682 *Sciences*. 2019;20(7):1-12. doi:10.3390/ijms20071677
- 57. Burmeister AR, Marriott I. The interleukin-10 family of cytokines and their role in the CNS.
 Frontiers in Cellular Neuroscience. 2018;12(November):1-13. doi:10.3389/fncel.2018.00458
- 685 58. Ringnér M. What is principal component analysis? *Nature Biotechnology*. 2008;26(3):303-304.
 686 doi:10.1038/nbt0308-303
- 687 59. Giuliani A. The application of principal component analysis to drug discovery and biomedical data. *Drug Discovery Today*. 2017;22(7):1069-1076. doi:10.1016/j.drudis.2017.01.005

689 60. Scriven JE, Graham LM, Schutz C, et al. A glucuronoxylomannan-associated immune signature,
690 characterized by monocyte deactivation and an increased interleukin 10 level, is a predictor of
691 death in cryptococcal meningitis. *Journal of Infectious Diseases*. 2016;213(11):1725-1734.
692 doi:10.1093/infdis/jiw007

- 693 61. Gerstein AC, Jackson KM, McDonald TR, et al. Identification of pathogen genomic differences
 694 that impact human immune response and disease during cryptococcus neoformans infection.
 695 mBio. 2019;10(4):1-22. doi:10.1128/mBio.01440-19
- 696 62. Traino K, Snow J, Ham L, et al. HIV-Negative Cryptococcal Meningoencephalitis Results in a
 697 Persistent Frontal-Subcortical Syndrome. *Scientific Reports*. 2019;9(1):1-9. doi:10.1038/s41598698 019-54876-7
- 699 63. Vanherp L, Poelmans J, Weerasekera A, et al. Trehalose as quantitative biomarker for in vivo
 700 diagnosis and treatment follow-up in cryptococcomas. *Translational research : the journal of*701 *laboratory and clinical medicine*. 2021;230:111-122. doi:10.1016/j.trsl.2020.11.001
- 64. Leite AGB, Vidal JE, Bonasser Filho F, Nogueira RS, Oliveira ACP de. Cerebral infarction
 related to cryptococcal meningitis in an HIV-infected patient: case report and literature review.
 The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2004;8(2):175-179. doi:10.1590/S1413-86702004000200008
- 65. Orsini J, Blaak C, Mahmoud D, Young-Gwang J. Massive cerebral edema resulting in brain death
 as a complication of cryptococcus neoformans meningitis. *Journal of Community Hospital Internal Medicine Perspectives*. 2015;5(1):3-6. doi:10.3402/jchimp.v5.26098
- 66. Jarvis JN, Meintjes G, Bicanic T, et al. Cerebrospinal Fluid Cytokine Profiles Predict Risk of
 Early Mortality and Immune Reconstitution Inflammatory Syndrome in HIV-Associated
 Cryptococcal Meningitis. *PLoS Pathogens*. 2015;11(4):1-17. doi:10.1371/journal.ppat.1004754
- 67. Jarvis JN, Casazza JP, Stone HH, et al. The phenotype of the cryptococcus-specific CD4+
 memory T-cell response is associated with disease severity and outcome in HIV-associated
 cryptococcal meningitis. *Journal of Infectious Diseases*. 2013;207(12):1817-1828.
 doi:10.1093/infdis/jit099
- 716 68. Qiao X, Zhang W, Zhao W. Role of CXCL10 in Spinal Cord Injury. Int J Med Sci.
 717 2022;19(14):2058-2070. doi:10.7150/ijms.76694
- 718 69. Teixeira AL, Gama CS, Rocha NP, Teixeira MM. Revisiting the Role of Eotaxin-1/CCL11 in
 719 Psychiatric Disorders. *Front Psychiatry*. 2018;9:241. doi:10.3389/fpsyt.2018.00241
- 70. Okafor EC, Hullsiek KH, Williams DA, et al. Correlation between blood and CSF compartment
 721 cytokines and chemokines in subjects with cryptococcal meningitis. *Mediators of Inflammation*.
 722 2020;2020. doi:10.1155/2020/8818044
- 71. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV
 immune reconstitution inflammatory syndrome after cryptococcal meningitis: A prospective
 cohort study. *PLoS Medicine*. 2010;7(12):1-14. doi:10.1371/journal.pmed.1000384
- 726 72. Lobo-Silva D, Carriche GM, Castro AG, Roque S, Saraiva M. Balancing the immune response in
 727 the brain: IL-10 and its regulation. *Journal of Neuroinflammation*. 2016;13(1):1-10.
 728 doi:10.1186/s12974-016-0763-8
- 729 73. Wake RM, Govender NP, Omar T, et al. Cryptococcal-related mortality despite fluconazole pre 730 emptive treatment in a cryptococcal antigen (CrAg) screen-and-treat programme. *Clinical*

- *infectious diseases : an official publication of the Infectious Diseases Society of America.*Published online June 2019. doi:10.1093/cid/ciz485
- 733 74. Meya D, Okurut S, Zziwa G, et al. Monocyte Phenotype and IFN-γ-Inducible Cytokine Responses
 734 Are Associated with Cryptococcal Immune Reconstitution Inflammatory Syndrome. *Journal of* 735 *Fungi*. 2017;3(2):28. doi:10.3390/jof3020028
- 736 75. Meya DB, Okurut S, Zziwa G, Cose S, Boulware DR, Janoff EN. HIV-Associated Cryptococcal
 737 Immune Reconstitution Inflammatory Syndrome Is Associated with Aberrant T Cell Function
 738 and Increased Cytokine Responses. *Journal of fungi (Basel, Switzerland)*. 2019;5(2):42.
 739 doi:10.3390/jof5020042
- 740 76. Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation. *Journal of periodontology*. 1993;64(5 Suppl):456-460.
- 742 77. Ehrlich LC, Hu S, Sheng WS, et al. Cytokine regulation of human microglial cell IL-8 production.
 743 *Journal of immunology (Baltimore, Md : 1950).* 1998;160(4):1944-1948.
- 744 78. Rosales C. Neutrophil: A cell with many roles in inflammation or several cell types? *Frontiers in* 745 *Physiology*. 2018;9(FEB):1-17. doi:10.3389/fphys.2018.00113
- 746 79. Guimarães-Costa AB, Nascimento MTC, Wardini AB, Pinto-Da-Silva LH, Saraiva EM. ETosis:
 747 A microbicidal mechanism beyond cell death. *Journal of Parasitology Research*.
 748 2012;2012(Table 1). doi:10.1155/2012/929743
- 80. Musubire AK, Meya DB, Rhein J, et al. Blood neutrophil counts in HIV-infected patients with
 cryptococcal meningitis: Association with mortality. *PloS one*. 2018;13(12):e0209337-e0209337.
 doi:10.1371/journal.pone.0209337
- 81. Grahl N, Shepardson KM, Chung D, Cramer RA. Hypoxia and fungal pathogenesis: To air or not to air? *Eukaryotic Cell*. 2012;11(5):560-570. doi:10.1128/EC.00031-12
- Biehl JW, Hullsiek KH, Okirwoth M, et al. Cerebral Oximetry for Detecting High-mortality Risk
 Patients with Cryptococcal Meningitis. Published online 2017:1-7. doi:10.1093/ofid/ofy105
- 83. Shimoda Y, Ohtomo S, Arai H, Ohtoh T, Tominaga T. Subarachnoid small vein occlusion due to
 inflammatory fibrosis—a possible mechanism for cerebellar infarction in cryptococcal
 meningoencephalitis: a case report. *BMC Neurology*. 2017;17(1):157. doi:10.1186/s12883-0170934-y
- 84. Hung CW, Chang WN, Kung CT, et al. Predictors and long-term outcome of seizures in human
 immuno-deficiency virus (HIV)-negative cryptococcal meningitis. *BMC Neurology*.
 2014;14(1):1-8. doi:10.1186/s12883-014-0208-x
- 85. Saito T, Saido TC. Neuroinflammation in mouse models of Alzheimer's disease. *Clinical and Experimental Neuroimmunology*. 2018;9(4):211-218. doi:10.1111/cen3.12475
- 86. Lu Y, Ma C, Chen R, et al. Development and validation of a new scoring system for the early diagnosis of tuberculous meningitis in adults. *Diagnostic Microbiology and Infectious Disease*.
 2021;101(2):115393. doi:10.1016/j.diagmicrobio.2021.115393

- 768 87. D'Inzeo T, Menchinelli G, De Angelis G, et al. Implementation of the eazyplex® CSF direct
 769 panel assay for rapid laboratory diagnosis of bacterial meningitis: 32-month experience at a
 770 tertiary care university hospital. *European Journal of Clinical Microbiology and Infectious*771 *Diseases*. 2020;39(10):1845-1853. doi:10.1007/s10096-020-03909-5
- 88. Sokol CL, Luster AD. The chemokine system in innate immunity. *Cold Spring Harbor Perspectives in Biology*. 2015;7(5):1-20. doi:10.1101/cshperspect.a016303
- 89. Veenstra M, León-Rivera R, Li M, Gama L, Clements JE, Berman JW. Mechanisms of CNS viral seeding by HIV+ CD14+ CD16+ monocytes: Establishment and reseeding of viral reservoirs contributing to HIV-associated neurocognitive disorders. *mBio*. 2017;8(5):1-15. doi:10.1128/mBio.01280-17
- Persidsky Y, Poluektova L. Immune Privilege and HIV-1 Persistence in the CNS. Vol 213.;
 2006:180-194. doi:10.1111/j.1600-065X.2006.00440.x
- Panackal AA, Wuest SC, Lin YC, et al. Paradoxical Immune Responses in Non-HIV
 Cryptococcal Meningitis. *PLoS Pathogens*. 2015;11(5):1-27. doi:10.1371/journal.ppat.1004884
- Kawakami K, Qureshi MH, Koguchi Y, Nakajima K, Saito A. Differential effect of Cryptococcus neoformans on the production of IL-12p40 and IL-10 by murine macrophages stimulated with lipopolysaccharide and gamma interferon. *FEMS Microbiology Letters*. 1999;175(1):87-94. doi:10.1016/S0378-1097(99)00172-X
- 786 93. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. *Nature* 787 *Reviews Immunology*. 2003;3(2):133-146. doi:10.1038/nri1001
- 94. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases. *Mediators of Inflammation*. 2017;2017. doi:10.1155/2017/3908061
- 95. Lee SC, Casadevall A, Dickson DW. Immunohistochemical localization of capsular
 polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis.
 The American journal of pathology. 1996;148(4):1267-1274.
- 794 96. Okurut S, Okafor E, Boulware DR, et al. Okurut, S., Okafor, E., Boulware, RD., Rhein J., 795 Manabe, CY., Olobo OJ., Meya BD., and Janoff, NE., (2023). Divergent neuroimmune signatures 796 and HIV-associated cryptococcal meningitis survival. Abstract and poster retrieved on July 28, 797 2023 CROI webseite. 489 ePoster. from 2023;(2023). 798 https://www.croiconference.org/abstract/divergent-neuroimmune-signatures-and-hiv-associated-799 cryptococcal-meningitis-survival/
- 97. Okurut, S. (2023) B cell responses, immune modulation and survival among patients with HIVassociated cryptococcal meningitis. [PhD. Thesis]. [Kampala, Uganda]: Makerere University.
- 802
- 803
- 804

805 14 TABLES

806 Table 1, Baseline Demographics of People With HIV-Associated cryptococcal meningitis by

- 807 Gender
- 808

Variables	Ν	Females Median (IQR) or N (%)	Ν	Men Median (IQR) or N (%)	P- value
Participants, N=419, n (%)		168 (40.1)		251 (59.9)	
Demographics					
Age, years	167	32 (28-38)	246	35 (30-40)	0.004
Weight, Kg	155	50 (47-60)	238	54 (50-60)	0.007
On ART, n (%)	167	73 (48.7)		125 (54.3)	
Duration of ART, days	77	167 (64-1109)	135	231 (29-1095)	
Signs and symptoms					
Headache at presentation, n (%)	168	161 (95.8)	251	240 (95.6)	
Duration of headache, days	161	14 (7-21)	240	14 (7-30)	
Cachexia, n (%)	167	72 (43.1)	246	112 (45.5)	
Photophobia, n (%)	166	57 (34.1)	145	66 (26.8)	

Seizures present, n (%)	168	22 (13.1)	246	42 (17.1)	
Altered mental status, n (%)	167	56 (33.5)	246	96 (39)	
Glasgow Coma Scale <15, n (%)	166	80 (47.9)	246	115 (46.7)	
Systolic blood pressure, mmHg	166	120.0 (105.8-131.3)	242	123.0 (112.8-138.3)	0.007
Diastolic blood pressure mmHg	166	79.5 (69.0-90.0)	242	80.0 (70.0-93.0)	
Blood Clinical analysis	<u>s</u>				
Glucose, mmol/L	75	5.8 (4.9-6.8)	111	5.7 (4.9-6.4)	
White blood cells, $x10^{9}/L$	156	3.5 (2.7-4.9)	226	3.5 (2.5-5.1)	
CD4 T cell counts/ μ L	162	23 (8-58)	234	15 (5-39)	0.004
CD8 T cell counts/µL	160	334 (168-632)	230	283 (172-481)	
Hemoglobin, g/dL	156	10.8 (9.1-12)	226	12.4 (10.4-13.7)	< 0.001
Platelets, x10 ⁹ /L	156	216 (144-270)	225	179 (128-245)	0.021
CSF Clinical analysis					
Glucose, mmol/L	55	3.3 (2.1-4.4)	78	4.6 (2.3-6)	0.033
Protein mg/dL	140	40 (23-96)	199	58 (25-113)	

White blood cells/µL	160	<5 (<5-34)	241	<5 (<5-45)
Opening pressure, mmH ₂ O	143	270 (180-424)	212	298 (220-427.5)
Cryptococcal culture, Log ₁₀ cfu/mL	152	4.9 (3.3-5.6)	223	4.7 (3.7-5.6)

809

810 Statistics: Mann-Whitney U-test, Chi-Square test. Not statistically significant variables had p-value

811 ≥0.05 at a 95% confidence interval. CFU - colony forming units. CSF - cerebrospinal fluid. ART -

antiretroviral therapy. Normal CSF proteins in adults: 15-60 mg/dL. Normal CSF glucose: 2.5 -4.4
 mmol/L.

814

815

817 Table 2, Differences in Baseline Immune Signature in Cerebrospinal Fluid Exudate by Gender

818 Among Patients with HIV-Associated Cryptococcal Meningitis.

Variables	<u>Females</u> , Median (IQR)	<u>Men</u> , Median (IQR)	P-value				
Participants, N=419	168 (40.1)	251 (59.9)					
Immune checkpoint inhibitor							
PD-L1/B7-H1	90.0 (41.0-170.6)	112.5 (53.4-205.9)	0.028				
T helper 1 cytokines							
TNF-α	37.4 (11.8-86.3)	49.2 (20.3-109.4)	0.048				
IL-2	5.0 (2.1-8.8)	5.1 (2.5-9.0)					
IFN-γ	3.8 (0.4-10.3)	5.2 (0.4-12.9)					
CD40 Ligand/TNFSF5	370.2 (73.1-636.4)	411.1 (188.2-715)					
CCL11/Eotaxin	15.0 (6.2-20.7)	14.5 (7.4-20.2)					
IL-12p70	5.2 (1.4-10.0)	6.0 (1.7-10.4)					
CXCL10/IP-10	2407.0 (1038.0-3037.0)	2394.0 (1161.0-3017.0)					
<u>T helper 2 cytokine</u>							
IL-4	1.2 (0.4-2.2)	1.3 (0.5-2.3)					
IL-13	22.3 (10.9-35.4)	21.9 (10.6-35.0)					
<u>T helper 17 cytokine</u>							

medRxiv preprint doi: https://doi.org/10.1101/2023.08.09.23293903; this version posted August 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license. CSF divergent-neuroimmune signatures by intragender-specific survival IL-17A 1.6(0.2-4.1)2.3 (0.2-5.4) **T** follicular helper cytokines IL-10 213.2 (144.7-325.2) 242.8 (161.6-348.3) **Innate myeloid cytokines** 0.001 IL-1RA/IL-1F3 4041.0 (1139.0-10005.0) 6142.0 (2582.0-10067.0) IL-15 2.8 (1.8-4.6) 3.6 (2.5-5.2) 0.003 IL-8/CXCL8 346.5 (148.0-1042.0) 380.4 (135.4-1118.0)

IL-6 142.4 (44.4-721.3) 209.3 (48.6-1344.0)

820

821 Cerebrospinal fluid cytokine differentiation with gender: Cytokine and chemokine levels were 822 measured in picogram per milliliter (pg/mL). Statistics: Mann-Whitney U-test. The statistically similar

823 variable had a p-value ≥ 0.05 at a 95% confidence interval.

824

825

826

828 Table 3. Univariate Difference in Baseline Levels of CSF Factors Associated with Gender

829 Survival Among Patients with HIV-Associated CM.

Cytokine, Pg/mL	<u>Females</u> Alive Median (IQR)	<u>Females</u> Died Median (IQR)	P- value	<u>Males</u> Alive Median (IQR)	<u>Males</u> Died Median (IQR)	P- value
Ν	71	79		136	94	
<u>T helper 1 cytoki</u>						
IL-2	6.0	4.3		4.5	5.2	
	(4.4-10.1)	(2.0-7.7)		(2.3-8.6)	(2.8-10.3)	
IFN-γ	5.2	2.1		3.8	6.0	
XX 10 5 0	(0.4-14.0)	(0.3-8.4)	0.010	(0.4-10.9)	(0.4-16.2)	
IL-12p70	7.6	3.6	0.018	6.0	6.0	
	(2.6-11.2)	(0.8-8.4)	0.041	(1.6-10.2)	(2.0-10.8)	
TNF-α	54.1	27.9	0.041	61.1	38.1	
	(15.8-108.5)	(8.3-69.4)	0.040	(27.4-104.0)	(15.4-115.5)	
CD40-L/	428.1	290.4	0.049	433.7	395.2	
TNFSF5	(115.7- 732.7)	(65.2-534.7)		(171.2-710.9)	(188.2-797.4)	
CCL11/Eotaxin	17.0	12.4	0.001	14.5	14.6	
	(11.4-21.6)	(3.3-18.6)		(7.2-20.1)	(9.2-20.5)	
CXCL10/-IP-10	2613.0	1590.0	0.001	2515.0	2369.0	
	(2071.0- 3330.0)	(497.1-2702.0)		(1432.0- 3016.0)	(974.1-3068.0)	
<u>T helper 2 cytoki</u>	nes					
IL-4	1.3	1.1		1.3	1.6	
	(0.6-2.6)	(0.3-2.1)		(0.5-2.5)	(0.7-2.3)	
IL-13	28.7	20.1	0.041	27.6	20.6	0.001
	(14.0-38.1)	(5.9-31.6)		(18.4-37.6)	(4.2-32.5)	
<u>T helper 17 cytol</u>				1		
IL-17A	2.8	0.9	< 0.001	2.8	2.2	
	(0.9-6.0)	(0.2-3.0)		(0.3 - 5.9)	(0.2-5.1)	
		egulatory cytokin	_			
IL-10	241.2	184.1	0.009	267.0	212.4	0.002
	(175.7-	(175.7-278.1)		(209.7-374.7)	(134.5-338.8)	
T	384.5)					
Innate-like cytok		2082.0		52(1.0	(201.0	
IL-1RA/IL-1F3	3830.0	3983.0		5361.0	6201.0	
	(12070.0- 10005.0)	(843.1 - 10011.0)		(2329.0-10032.0)	(2378.0- 10078.0)	
IL-6	155.7	123.4		202.4	189.0	
1L-0	(36.3-962.1)	(40.6-514.5)		(48.3-1267.0)	(41.6-1305.0)	
IL-8 (CXCL8)	460.0	303.5		329.1	384.9	
1L-0 (CACLO)	(147.8-	(141.6-916.4)		(162.9-938.3)	(112.4-1153.0)	
IL-15	1042.0) 2.8	2.7		3.2	4.0	0.002
1L-13	2.0	2.1		5.2	4.0	0.002

	(1.8-5.3)	(1.7-4.0)	(2.3-4.6)	(2.9-5.9)	
Immune chec	<u>kpoint factor</u>				
PD-L1	107.3	72.2	126.9	101.1	
	(44.2-174.9)	(36.0-158.5)	(67.1-192.0)	(50.5-216.6)	

831

- 832 Cerebrospinal fluid cytokine differentiation with gender-specific survival: Statistics: Mann-Whitney
- 833 U-test, not statistically significant variables had a p-value ≥ 0.050 at a 95% confidence interval.

834

836 Table 4, Baseline Independent Factors Predicting Intragender 18 Weeks Survival Among

837 Patients with HIV-Associated Cryptococcal Meningitis on Antifungal Therapy.

Variables	Females	P-value	Men	P-value
Cytokines, Log ₂ (Pg/mL)	Odds ratio estimate		Odds ratio estimate	
	(95% CI for profile likelihood)		(95% CI for profile likelihood)	
Survival at 18 weeks, N (%)	71 of 150 (47.3)		136 of 230 (59.1)	0.024
N (range)/model	Survived (n=63 to n=70)		Survived (n=118 to n=131)	
	Died (n=60 to n=71)		Died (n=78 to n=91)	
Model 1, survival adjusted 1	for cytokine			
CCL11/Eotaxin	0.42 (0.20-0.80)	0.014	1.65 (1.00-2.76)	
CXCL10/-IP-10	0.48 (0.27-0.79)	0.006	1.03 (0.76-1.40)	
IL-8/CXCL8	0.93 (0.65-1.31)		1.38 (1.03-1.88)	0.034
IL-15	0.96 (0.57-1.62)		1.88 (1.20-3.04)	0.007
Model 2, survival adjusted 1	<u>for age, weight, systolic</u>	<u>: blood pr</u>	essure and cytokines	
CCL11/Eotaxin	0.35 (0.16-0.69)	0.005	1.55 (0.94-2.60)	
CXCL10/IP-10	0.55 (0.30-0.96)	0.042	1.00 (0.73-1.37)	
IL-10	2.26 (1.00-5.11)	0.044	0.65 (0.32-1.27)	
IL-15	0.86 (0.48-1.50)		1.63 (1.03-2.64)	0.040

Model 3, survival adjusted	<u>for hemoglobin, plate</u>	<u>lets count,</u>	CD4 counts and cytok	<u>tines</u>
CD4 T cell counts/ μL	0.99 (0.98-1.00)	0.039	1.00 (0.99-1.01)	
IL-2	1.94 (1.13-3.78)	0.025	0.59 (0.30-1.06)	
IL-10	2.33 (1.04-5.39)	0.038	0.73 (0.34-1.51)	
CCL11/Eotaxin	0.29 (0.12-0.63)	0.004	1.044 (0.970-1.129)	
CXCL10/IP-10	0.45 (0.25-0.76)	0.004	0.98 (0.69-1.38)	
IL-8/CXCL8	0.92 (0.64-1.32)		1.69 (1.17-2.58)	0.009
IL-15	0.81 (0.43-1.49)		1.79 (1.05-3.20)	0.041
Hemoglobin, g/dL	0.82 (0.66-1.02)		0.82 (0.70-0.94)	0.006
Model 4, survival adjusted	for sodium, potassiun	n, and cyto	kines	
CCL11/Eotaxin	0.32 (0.12-0.70)	0.009	1.74 (1.01-3.05)	0.048
CXCL10/IP-10	0.52 (0.27-0.92)	0.033	1.10 (0.79-1.55)	
IL-8/CXCL8	0.87 (0.59-1.28)		1.41 (1.02-2.00)	0.044
IL-15	0.89 (0.48-1.66)		2.36 (1.43-4.12)	0.001
Sodium, mmol/L	0.96 (0.88-1.04)		0.87 (0.93-0.98)	0.011
Potassium, mmol/L	0.49 (0.24-0.95)	0.044	0.99 (0.62-1.59)	

839

840 Multivariate adjusted models of gender-specific associated factors (univariate gender-specific survival-841 associated factors in Table 3), were interrogated with statistically different gender-associated

demographic variables (Table 1). Odds ratios represent the independent likelihood of survival based 842 843 on levels of the indicated factor with an adjusted multivariate logistic regression model. Statistic: 844 intragender (male or female) multiple logistic regression. Not statistically significant variables had

845 adjusted p-value ≥ 0.05 at a 95% confidence interval. The main effect of variables on gender survival.

846 **15 FIGURES**

847 Figure 1




Figure 1. The proportion of cases with HIV-associated CM by gender and of related survival by gender
 in 21 published case series. These studies include 38,485 cases with 5,834 reported deaths, which
 accounted for a 15.2% case fatality rate (see Supplementary Table 1 for details and references ^{7,9,19,26,28–}
 ⁴⁴. Bars show median values. 5 studies report survival by gender (4 references and this report;
 Supplemental Table 1).

- 854
- 855
- 856

857 Figure 2

Kaplan-Meier: by 18-Weeks Mortality 100 Probability of Survival Men, 59. % Survival 50· Women, 47.3 % Survival Log-rank (Mantel-Cox) HR = 1.4 (Cl 1.0 - 1.9) p = 0.023At 18 weeks Women Men Censored 135 71 Deaths 79 94 0. Weeks Ó 2 4 10 12 14 6 8 16 18 150 106 80 76 72 70 66 40 Women At risk 229 180 159 147 143 83 Men

858

Figure 2. Survival among people with HIV-associated cryptococcal meningitis. The p-value <0.05 is
 statistically different.

861

862


863

864

_ _ _

865





869 Figure 3. Projection of cytokine responses on Eigenvector correlation covariates on PC1 and PC 2 870 (axes) using unsupervised principal component analysis. Baseline cerebrospinal fluid (CSF) immune 871 signature among participants who were diagnosed with HIV-associated CM showed distinct clusters by gender and by survival. PC - Principal component. Dots - show individual cytokines produced 872 among participants projected on Eigenvector correlation covariates. Variables near the center (0; zero) 873 874 are uncorrelated to the model and variables further away from the center (0; zero) are strongly 875 correlated to the model. Variables among all cytokine projected on the variety of CSF cytokine patterns 876 among participants by host survival (Figure 3A). The CSF secreted cytokines clustering by gender 877 (Figure 3B). Cytokine clustering by female survival (Figure 3C). Cytokine clustering by men's survival 878 (Figure 3D).

- 879
- 880
- 881
- 882

Group Analyzed	Participa gender	nts by	Participar Survival	nts by	Females Survival	by	Males Survival	by
PC summary	PC1	PC2	PC1	PC2	PC1	PC2	PC1	PC2
Eigenvalue	9.8	7.3	9.5	7.6	10.1	9.5	7.6	4.7
Proportion of variance (%)	30.6	22.7	29.7	23.9	31.7	29.7	23.9	14.6
Cumulative proportion of variance (%)	30.6	53.3	29.7	53.6	31.7	61.3	23.9	38.5

883

Adjacent Table to Figure 3: PC1 shows the highest variance of loading on a single vector. PC2 shows the cumulative variance of loading that is orthogonal to PC1 with a center 0. Yet negative variables show the presence of hidden (latent) variables that can be only determined through inference using mathematical modeling or through direct measurement alongside observed variables (those with positive variance on PCA). The great the Eigenvalues than one (1) the greater the predictability power of the variable in determining the hidden or latent variance to the outcome.

890

891

893 **1. SUPPLEMENTARY MATERIALS**

894 Supplementary Table S1. Reported gender-Associated Survival Among People with HIV-895 Associated Cryptococcal Meningitis.


Article	Number of cases	Females N (%)	Males N (%)	Total fatality N (%)	Female fatality N (%)	Male fatality N (%)
Pappas 2004 28	70	13 (18.6)	57 (81.4)			
Boulware 2010 ²⁹	170	70 (48.0)	100 (58.0)	85 (50.0) *		
Baldassarre 2014 44	76	30 (39.5)	46 (60.5)	30 (39.5)	12 (40.0	18 (39.1)
Jarvis 2014 ²⁶	481	231 (48.0)	250 (52.0)	163 (34.0) #	79 (34.2)	84 (33.6)
Boulware 2014 ⁹	177	84 (47.5)	93 (52.5)	67 (37.9)		
Rajasingham 2015 ³⁰	188	100	88 (47.0)	45 (24.0)*		
Meya 2015 ¹⁹	46	25 (63.0)		14 (30.0) =		
George 2017 ³¹	158	54 (34.1)	108 (65.9)	41 (26.0) *		
Rhein 2017 ³²	172		113 (66.0)	69 (40.0)		
Kashef Hamadani 2018 ³³	55	10 (18.2)	45 (81.8)			
Meya 2019 ³⁴	3359		1522* (47.1)	949 (28.3) ^		
Pastick 2019 35	821	334 (40.7)	587 (58.7)	334 (41.3)		

Lakoh 2020 ³⁶	8	7	1	2 (25.0) *		
Marr 2020 37	145	50 (35.5)	95 (65.5)			
Lee 2021 ³⁸	76	28 (36.8)	48 (63.2)	10 (80.3)		
Stadelman 2021 ⁷	977	400 (40.9)	577 (59.1)	445 (45.5) [#]	198 (50.0)	247 (43.0)
Kalata 2021 ³⁹	678		390 (57.5)	251 (37.0) #		
Mansoor 2021 ⁴⁰	29066	6787 (23.3)	22279 (76.6)	2877 (9.9) ^a		
Deiss 2021 41	87			33 (37.9) =		
Zhao 2021 42	386	83 (21.5)	303 (78.5)	58 (15.0) ^a	18 (21.7)	40 (15.2)
Jarvis 2022 ⁴³	814	323 (39.7)	491 (60.3)	218 (26.9) #		
Okurut (current)	380	150 (39.5)	230 (60.5)	173 (45.5)	79 (52.7)	94 (40.9)

897

898 * - hospital deaths. = - 12 weeks deaths. # - 10 weeks deaths. ^ - 24 weeks. a – all deaths.

900



903

920 Supplementary Figure 1. Spearman's correlation of regulatory elements IL-10 and PD-L1 by gender 921 among multivariate predictors of gender-specific survival among females and males who died on antifungal treatment. A-C correlation of IL-10 with A - CCL11/Eotaxin, B - CXCL10/IP-10, and C -922 923 IL-15 among females and males who died on antifungal treatment, (i - ii, respectively). D – correlation 924 of IL-8 with IL-15 among females and males who died on antifungal treatment. E-H – correlation of 925 PD-L1 with E – IL12p70, F – IL-15, G – CXCL10, and H – CCL11 among females and males who

- 926 died on antifungal treatment (i ii), respectively). Notable, among females and males who survived,
- 927 the responses were similar and positively correlated across the panels.